Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary recombinant human activated protein C for LPS-induced lung inflammation
NL-OMON27608Active, not recruiting
- Sponsor
- Prof. Dr. Tom van der Poll, principal investigator. Center of Experimental Molecular Medicine, AMC-UvA, Amsterdam, The Netherlands
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of drotrecogin alfa in No single canonical disease name; "pulmonary inflammation" is a descriptive term, not a specific disease (5 arms), sponsored by Prof. Dr. Tom van der Poll, principal investigator. Center of Experimental Molecular Medicine, AMC-UvA, Amsterdam, The Netherlands. Primary endpoints: Effect of direct intrapulmonary rhAPC on LPS-induced lung inflammation and Coagulation response in dose-escalation phase. Started Sep 2008; status: active, not recruiting.
02
Drugs
drotrecogin alfa
03
Conditions
No single canonical disease name; "pulmonary inflammation" is a descriptive term, not a specific disease.
Beyond the preview
Go deeper on NL-OMON27608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27608.